Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)
Status: | Completed |
---|---|
Conditions: | Migraine Headaches |
Therapuetic Areas: | Neurology |
Healthy: | No |
Age Range: | 18 - 65 |
Updated: | 4/21/2016 |
Start Date: | April 2013 |
End Date: | September 2014 |
This study will evaluate the use of the Assessment of Chronic Migraine Impacts (ACM-I)
Questionnaire in assessing the impact and benefit of treatment with onabotulinumtoxinA
(BOTOX®) in adults with chronic migraine.
Questionnaire in assessing the impact and benefit of treatment with onabotulinumtoxinA
(BOTOX®) in adults with chronic migraine.
Inclusion Criteria:
- History of chronic migraine for at least 6 months prior to the screening visit
- Fifteen or more headache days during the 4-week screening period (≥4 headache
episodes lasting ≥4 hours and ≥50 % of headache days are migraine)
Exclusion Criteria:
- Conditions causing chronic facial pain such as Temporomandibular Disorder (TMD) and
fibromyalgia
- Use of headache prophylaxis medication within 4 weeks of the screening visit
- Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis
- Previous use of any botulinum toxin of any serotype for any reason
- Skin infections or acne that would interfere with the injection sites
- Acupuncture, transcutaneous electrical nerve stimulation (TENS), cranial traction,
dental splints for headache, nociceptive trigeminal inhibition, occipital nerve block
treatments, or injection of anesthetics/steroids within 4 weeks of screening.
We found this trial at
1
site
Click here to add this to my saved trials